(UroToday.com) Despite a number of therapies with proven survival benefit, the prognosis of patients with advanced urothelial carcinoma remains poor. In addition to cytotoxic chemotherapy using a platinum-based regime, the use of checkpoint inhibitors has demonstrated promise. However, long-term responses are rare.